References

Wegovy (semaglutide injection) prescribing information.

US Food and Drug Administration, 2024

Current FDA label for Wegovy (semaglutide 2.4 mg). Includes weight-management indication, dosing schedule, contraindications, warnings, and clinical trial data.

Ozempic (semaglutide) prescribing information.

US Food and Drug Administration, 2024

Current FDA label for Ozempic (semaglutide 0.25-2.0 mg). T2D indication, cardiovascular risk reduction, dosing, contraindications, and warnings.

Zepbound (tirzepatide) prescribing information.

US Food and Drug Administration, 2024

Current FDA label for Zepbound. Weight management + obstructive sleep apnea indications (OSA added December 2024). Dosing 2.5-15 mg weekly.

Mounjaro (tirzepatide) prescribing information.

US Food and Drug Administration, 2024

Current FDA label for Mounjaro. T2D indication only (weight management is Zepbound). Dosing, contraindications, and DPP-4 / sulfonylurea interaction warnings.

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

New England Journal of Medicine, 2021 · DOI: 10.1056/NEJMoa2032183

STEP-1: 68-week trial of semaglutide 2.4 mg in 1961 adults with BMI ≥30 (or ≥27 with comorbidity). Mean body weight reduction 14.9% vs 2.4% placebo.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.

New England Journal of Medicine, 2022 · DOI: 10.1056/NEJMoa2206038

SURMOUNT-1: 72-week trial of tirzepatide 5/10/15 mg in 2539 adults with BMI ≥30. Mean body weight reduction up to 20.9% at the 15 mg dose.

Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205.

New England Journal of Medicine, 2024 · DOI: 10.1056/NEJMoa2404881

SURMOUNT-OSA: 52-week trial of tirzepatide for moderate-to-severe OSA in adults with obesity. AHI reduction ~50%; disease resolution in 43%.

Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425.

JAMA, 2021 · DOI: 10.1001/jama.2021.3224

STEP-4: After 20 weeks titration on semaglutide, randomization to continue vs placebo. Discontinuation associated with substantial weight regain.

Aronne LJ, Sattar N, Horn DB, et al. Continued Tirzepatide vs Withdrawal to Placebo on Weight Reduction. JAMA. 2024;331(1):38-48.

JAMA, 2024 · DOI: 10.1001/jama.2023.24945

SURMOUNT-4: Continuation vs withdrawal of tirzepatide after a 36-week lead-in. Discontinuation led to 14% weight regain over the following 52 weeks.

Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30(1):168-176.

Nature Medicine, 2024 · DOI: 10.1038/s41591-023-02672-2

1.6M-record EHR analysis comparing semaglutide vs non-GLP-1 anti-obesity / anti-diabetes drugs. No excess suicidal ideation; some signal toward reduction.

Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).

American Diabetes Association, 2024

Annual evidence-based standards of care. Establishes GLP-1 RAs as first-line injectable therapy for many adults with T2D, especially with ASCVD or HF.

AACE / Obesity Society Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocr Pract. 2022;28(10):896-924.

American Association of Clinical Endocrinology, 2022

AACE/TOS framework treating obesity as a chronic disease. Establishes BMI ≥27 with comorbidity as the FDA-aligned threshold for anti-obesity pharmacotherapy.

Coverage and Payment of GLP-1 Medications. CMS Manual System Pub 100-04.

Centers for Medicare & Medicaid Services, 2024

Medicare Part D coverage rules. Weight-management-only indications statutorily excluded; T2D and OSA (Zepbound) coverage permitted under specific criteria.

FDA Drug Shortages — Semaglutide injection products.

US Food and Drug Administration, 2025

Authoritative FDA shortage tracker. The May 2025 declaration that the semaglutide injection shortage was resolved underpins current compounding restrictions.

FDA approves first medication for obstructive sleep apnea. FDA News Release.

US Food and Drug Administration, 2024

December 2024 press release announcing FDA approval of Zepbound for moderate-to-severe OSA in adults with obesity. The first weight-loss drug approved for OSA.

Wegovy Savings Card and patient-assistance program.

Novo Nordisk, 2026

Manufacturer commercial-insurance savings program: most eligible commercially-insured patients pay $0-$499/month. Income-based patient-assistance program is separate.

LillyDirect — self-pay program for Zepbound and Mounjaro.

Eli Lilly and Company, 2026

Direct-to-consumer self-pay program for Lilly GLP-1s. Cash price of $499/month for Zepbound is among the lowest brand-name options in 2026.